Dose intensity and high dose therapy. Two different concepts
暂无分享,去创建一个
[1] R. Livingston,et al. Feasibility of dose–intensive continuous 5–fluorouracil, doxorubicin, and cyclophosphamide as adjuvant therapy for breast cancer , 1993, Cancer.
[2] B. Teicher,et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] C. Spurr,et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. , 1991, The New England journal of medicine.
[4] M. Nooij,et al. "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808). , 1991, European journal of cancer.
[5] M. Raffeld,et al. bcl-1, t(11;14), and mantle cell-derived lymphomas. , 1991, Blood.
[6] W. Hryniuk,et al. The calculation of received dose intensity. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] G. Hortobagyi,et al. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] M. Gent,et al. A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] W. Wolberg,et al. Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] R. Livingston,et al. Combination chemotherapy and high‐dose cyclophosphamide intensification for poor prognosis breast cancer. A southwest oncology group study , 1989, Cancer.
[11] R. Strieter,et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxofylline , 1988 .
[12] I. Tannock,et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] M. Tattersall,et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. , 1987, The New England journal of medicine.
[14] R. Livingston,et al. Combination chemotherapy and systemic irradiation consolidation for poor prognosis breast cancer , 1987, Cancer.
[15] G. Hortobagyi,et al. Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] G. Janossy. Bone marrow purging. , 1987, Immunology today.
[17] M. Levine,et al. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] W. Hryniuk,et al. The importance of dose intensity in chemotherapy of metastatic breast cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] G. Bonadonna,et al. Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] G. Hortobagyi,et al. Complete remissions in metastatic breast cancer treated with combination drug therapy. , 1979, Annals of internal medicine.
[21] J. O'fallon,et al. Complete responders to chemotherapy in metastatic breast cancer. Characterization and analysis. , 1979, JAMA.